19:37 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and mouse studies identified methyloxymorphone-based dual MOR/DOR agonists that could help treat pain. Chemical synthesis and in vitro testing of methyloxymorphone analogs yielded six compounds that bound MOR and DOR with...
19:30 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Advisory panel narrowly rejects olicerideine for acute pain

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of oliceridine (TRV130) from Trevena Inc. (NASDAQ:TRVN) to manage moderate to severe pain in adults for whom IV opioids are warranted. Panelists...
22:05 , Oct 11, 2018 |  BC Extra  |  Company News

Advisory panel narrowly rejects oliceridine for acute pain

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of oliceridine (TRV130) from Trevena Inc. (NASDAQ:TRVN) to manage moderate to severe pain in adults for whom IV opioids are warranted. Panelists...
21:37 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Cell culture and mouse studies identified a peptide-based antagonist of the OPRD1/MOR heterodimer that could help treat opiate withdrawal. Chemical synthesis and testing in cell-based competitive binding and activity assays of conjugates linking...
18:57 , May 31, 2018 |  BC Innovations  |  Translation in Brief

Myocardial marker

A group at the Hebrew University of Jerusalem has developed a non-invasive method to detect circulating cell-free DNA from dying cardiomyocytes that could complement existing tests used to diagnose or monitor cardiac disease, and serve...
16:19 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Plasma levels of unmethylated RFLNA cfDNA could help diagnose MI or sepsis. In 70 patients with acute MI and 201 patients with sepsis, levels of unmethylated RFLNA cfDNA were higher than in...
20:27 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Kura's tipifarnib meets in Phase II for SCCHN

Kura Oncology Inc. (NASDAQ:KURA) said tipifarnib met the primary endpoint in a Phase II trial to treat v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the head and...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Sep 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Biased against pain

In a departure from the rote tweaking of morphinan structures to find better and safer opioids, an academic collaboration has used a powerful, computer-based screen of more than 3 million molecules to identify a new...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: κ opioid receptor (KOR; OPRK1); µ opioid receptor (MOR; OPRM1); opioid receptor δ1 (OPRD1; DOR); prepronociceptin (PNOC; NOP)

Neurology INDICATION: Pain; diabetic neuropathy In vitro, mouse and rat studies identified two agonists of KOR , MOR and OPRD1 and antagonists of PNOC that could help treat neuropathic pain and diabetic neuropathy. Chemical synthesis...